Search

Your search keyword '"Hervas D"' showing total 130 results
Start Over Author "Hervas D"
130 results on '"Hervas D"'

8. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids

Author

Alcala, N., Leblay, N., Gabriel, A. A. G., Mangiante, L., Hervas, D., Giffon, T., Sertier, A. S., Ferrari, A., Derks, J., Ghantous, A., Delhomme, T. M., Chabrier, A., Cuenin, C., Abedi-Ardekani, B., Boland, A., Olaso, R., Meyer, V., Altmuller, J., Le Calvez-Kelm, F., Durand, G., Voegele, C., Boyault, S., Moonen, L., Lemaitre, N., Lorimier, P., Toffart, A. C., Soltermann, A., Clement, J. H., Saenger, J., Field, J. K., Brevet, M., Blanc-Fournier, C., Galateau-Salle, F., Le Stang, N., Russell, P. A., Wright, G., Sozzi, G., Pastorino, U., Lacomme, S., Vignaud, J. M., Hofman, V., Hofman, P., Brustugun, O. T., Lund-Iversen, M., Thomas de Montpreville, V., Muscarella, L. A., Graziano, P., Popper, H., Stojsic, J., Deleuze, J. F., Herceg, Z., Viari, A., Nuernberg, P., Pelosi, G., Dingemans, A. M. C., Milione, M., Roz, L., Brcic, L., Volante, M., Papotti, M. G., Caux, C., Sandoval, J., Hernandez-Vargas, H., Brambilla, E., Speel, E. J. M., Girard, N., Lantuejoul, S., McKay, J. D., Foll, M., and Fernandez-Cuesta, L.

Published
2019
Full Text
View/download PDF

12. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

Author

Aparicio, J., Maroto, P., García del Muro, X., Sánchez-Muñoz, A., Gumà, J., Margelí, M., Sáenz, A., Sagastibelza, N., Castellano, D., Arranz, J.A., Hervás, D., Bastús, R., Fernández-Aramburo, A., Sastre, J., Terrasa, J., López-Brea, M., Dorca, J., Almenar, D., Carles, J., Hernández, A., and Germà, J.R.

Published
2014
Full Text
View/download PDF

16. 20733. HISTORIA NATURAL DE PACIENTES CON ATROFIA MUSCULAR ESPINAL CON 3 Y 4 COPIAS DEL GEN SMN2. DATOS DEL REGISTRO NACIONAL ESPAÑOL (CUIDAME)

Author

Puig Cruz, L., Aragón Gawinska, K., Fernández García, M., Nacimiento Osorio, A., Paradas, C., Sotoca, J., Povedano, M., Moreno Escribano, A., Henao, M., Gil Polo, C., Rojas García, R., Gómez Caravaca, M., Grimalt, M., Fernández Torron, R., Jericó, I., García Campos, Ó., Toledo Bravo de Laguna, L., Hervás, D., Tizzano, E., and Vázquez Costa, J.

Published
2024
Full Text
View/download PDF

18. OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery

Author

Lago, V., Segarra-Vidal, B., Cappucio, S., Angeles, M. A., Fotopoulou, C., Muallem, M. Z., Manzanedo, I., Iglesias, J. L. S., Chacon, E., Padilla-Iserte, P., Fagotti, Anna, Ferron, G., Kluge, L., Vargiu, V., Del, M., Scambia, Giovanni, Minig, L., Tejerizo, A., Segovia, M. G., Cascales-Campos, P. A., Gil-Moreno, A., Chiva, L., Rinne, N., Martinez, A., Matute, L., Gurrea, M., Sala Climent, L., Montesinos, M., Hervas, D., Domingo, S., Fagotti A. (ORCID:0000-0001-5579-335X), Scambia G. (ORCID:0000-0003-2758-1063), Lago, V., Segarra-Vidal, B., Cappucio, S., Angeles, M. A., Fotopoulou, C., Muallem, M. Z., Manzanedo, I., Iglesias, J. L. S., Chacon, E., Padilla-Iserte, P., Fagotti, Anna, Ferron, G., Kluge, L., Vargiu, V., Del, M., Scambia, Giovanni, Minig, L., Tejerizo, A., Segovia, M. G., Cascales-Campos, P. A., Gil-Moreno, A., Chiva, L., Rinne, N., Martinez, A., Matute, L., Gurrea, M., Sala Climent, L., Montesinos, M., Hervas, D., Domingo, S., Fagotti A. (ORCID:0000-0001-5579-335X), and Scambia G. (ORCID:0000-0003-2758-1063)

Abstract

Objective: The objective of the present study was to define and validate an anastomotic leak prognostic score based on previously described and reported anastomotic leak risk factors (OVA-LEAK: https://n9.cl/ova-leakscore) and to establish if the use of OVA-LEAK score is better than clinical criteria (surgeon's choice) selecting anastomosis to be protected with a diverting ileostomy. Material & methods: This is a retrospective, multicentre cohort study that included patients who underwent cytoreductive surgery for primary advanced or relapsed ovarian cancer with colorectal resection and anastomosis between January 2011 and June 2021. Data from patients already included in the previous predictive model were not considered in the present analysis. To validate the performance of our logistic regression model, we used the OVA-LEAK formula (Annex I: https://n9.cl/ova-leakscore) for estimating leakage probabilities in a new independent cohort. Then, receiver operating characteristic (ROC) analysis was performed and area under the curve (AUC) was used to measure the performance of the model. Additionally, the Brier score was also estimated. 95% confidence intervals (CI) for each of the estimated performance measures were also calculated. Results: 848 out of 1159 recruited patients were finally included in the multivariable logistic regression model validation. The AUC of the new cohort was 0.63 for predicting anastomotic leak. Considering a cut-off point of 22.1% to be ‘positive’ (to get a leak) this would provide a sensitivity of 0.45, specificity of 0.80, positive predictive value of 0.09 and negative predictive value of 0.97 for anastomotic leak. If we consider this cut-off point to select patients at risk of leak for bowel diversion, up to 22.5% of the sampled patients would undergo a diverting ileostomy and 47% (18/40) of the anastomotic leaks would be ‘protected’ with the stoma. Nevertheless, if we consider only the ‘clinical criteria’ for performing or not a div

Published
2022

20. MicroRNAs and markers of neutrophil activation as predictors of early incidental post-surgical pulmonary embolism in patients with intracranial tumors

Author

Oto, J, Plana, E, Solmoirago, M, Fernandez-Pardo, A, Hervas, D, Cana, F, Espana, F, Artoni, A, Bucciarelli, P, Carrabba, G, Navarro, S, Merati, G, Medina, P, Oto J., Plana E., Solmoirago M. J., Fernandez-Pardo A., Hervas D., Cana F., Espana F., Artoni A., Bucciarelli P., Carrabba G., Navarro S., Merati G., Medina P., Oto, J, Plana, E, Solmoirago, M, Fernandez-Pardo, A, Hervas, D, Cana, F, Espana, F, Artoni, A, Bucciarelli, P, Carrabba, G, Navarro, S, Merati, G, Medina, P, Oto J., Plana E., Solmoirago M. J., Fernandez-Pardo A., Hervas D., Cana F., Espana F., Artoni A., Bucciarelli P., Carrabba G., Navarro S., Merati G., and Medina P.

Abstract

Venous thromboembolism (VTE) is a common complication of cancer that severely increases morbidity and mortality. Patients with intracranial tumors are more likely to develop VTE than patients with cancers at other sites. Conversely, limited tools exist to identify patients with high thrombotic risk. Upon activation, neutrophils release their content through different mechanisms triggering thrombosis. We explored the ability of microRNAs (miRNAs) and plasma markers of neutrophil activation measured before surgery to predict the risk of early post-surgical pulmonary embolism (PE) in glioma and meningioma patients. We recruited and prospectively followed 50 patients with glioma and 50 with meningioma, 34% of whom in each group developed an early objectively-diagnosed post-surgical PE. We measured miRNA expression and neutrophil markers (cell-free DNA, nucleosomes, calprotectin and myeloperoxidase) before surgery. In glioma patients, we adjusted and validated a predictive model for post-surgical PE with 6 miRNAs: miR-363-3p, miR-93-3p, miR-22-5p, miR-451a, miR-222-3p and miR-140-3p (AUC = 0.78; 95% Confidence Interval (CI) [0.63, 0.94]) and another with cfDNA and myeloperoxidase as predictors (AUC = 0.71; 95%CI [0.52, 0.90]). Furthermore, we combined both types of markers and obtained a model with myeloperoxidase and miR-140-3p as predictors (AUC = 0.79; 95%CI [0.64, 0.94]). In meningioma patients we fitted and validated a predictive model with 6 miRNAs: miR-29a-3p, miR-660-5p, miR-331-3p, miR-126-5p, miR-23a-3p and miR-23b-3p (AUC = 0.69; 95%CI [0.52, 0.87]). All our models outperformed the Khorana score. This is the first study that analyzes the capability of plasma miRNAs and neutrophil activation markers to predict early post-surgical PE in glioma and meningioma patients. The estimation of the thrombotic risk before surgery may promote a tailored thromboprophylaxis in a selected group of high-risk patients, in order to minimize the incidence of PE and avoid bleeding

Published
2020

23. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery

Author

Padilla-Iserte P, Lago V, Tauste C, Díaz-Feijoo B, Gil-Moreno A, Oliver R, Coronado P, Martín-Salamanca MB, Pantoja-Garrido M, Marcos-Sanmartin J, Gilabert-Estellés J, Lorenzo C, Cazorla E, Roldán-Rivas F, Rodríguez-Hernández JR, Sánchez L, Muruzábal JC, Hervas D, and Domingo S

Subjects
endometrial cancer, minimally invasive surgery, oncological safety, overall survival, recurrence, recurrence-free survival, uterine manipulator
Abstract

There are limited data available to indicate whether oncological outcomes might be influenced by the uterine manipulator, which is used at the time of hysterectomy for minimally invasive surgery in patients with endometrial cancer. The current evidence derives from retrospective studies with limited sample sizes. Without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience.

Published
2021

25. Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors

Author

Mendez, R, Balanza-Martinez, V, Luperdi, SC, Estrada, I, Latorre, A, Gonzalez-Jimenez, P, Feced, L, Bouzas, L, Yepez, K, Ferrando, A, Hervas, D, Zaldivar, E, Reyes, S, Berk, M, Menendez, R, Mendez, R, Balanza-Martinez, V, Luperdi, SC, Estrada, I, Latorre, A, Gonzalez-Jimenez, P, Feced, L, Bouzas, L, Yepez, K, Ferrando, A, Hervas, D, Zaldivar, E, Reyes, S, Berk, M, and Menendez, R

Abstract

BACKGROUND: The general medical impacts of coronavirus (COVID-19) are increasingly appreciated. However, its impact on neurocognitive, psychiatric health and quality of life (QoL) in survivors after the acute phase is poorly understood. We aimed to evaluate neurocognitive function, psychiatric symptoms and QoL in COVID-19 survivors shortly after hospital discharge. METHODS: This was a cross-sectional analysis of a prospective study of hospitalized COVID-19 survivors followed up for 2 months after discharge. A battery of standardized instruments evaluating neurocognitive function, psychiatric morbidity and QoL (mental and physical components) was administered by telephone. RESULTS: Of the 229 screened patients, 179 were included in the final analysis. Amongst survivors, the prevalence of moderately impaired immediate verbal memory and learning was 38%, delayed verbal memory (11.8%), verbal fluency (34.6%) and working memory (executive function) (6.1%), respectively. Moreover, 58.7% of patients had neurocognitive impairment in at least one function. Rates of positive screening for anxiety, depression and post-traumatic stress disorder were 29.6%, 26.8% and 25.1%, respectively. In addition, 39.1% of the patients had psychiatric morbidity. Low QoL for physical and mental components was detected in 44.1% and 39.1% of patients respectively. Delirium and psychiatric morbidity were associated with neurocognitive impairment, and female gender was related with psychiatric morbidity. CONCLUSION: Hospitalized COVID-19 survivors showed a considerable prevalence of neurocognitive impairment, psychiatric morbidity and poor QoL in the short term. It is uncertain if these impacts persist over the long term.

Published
2021

26. Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer's Disease

Author

Pena-Bautista, C, Baquero, M, Lopez-Nogueroles, M, Vento, M, Hervas, D, and Chafer-Pericas, C

Subjects
biomarker, lipid peroxidation, Alzheimer's disease, blood-brain barrier, cerebrospinal fluid, mass spectrometry
Abstract

Previous studies showed a relationship between lipid oxidation biomarkers from plasma samples and Alzheimer's Disease (AD), constituting a promising diagnostic tool. In this work we analyzed whether these plasma biomarkers could reflect specific brain oxidation in AD. In this work lipid peroxidation compounds were determined in plasma and cerebrospinal fluid (CSF) samples from AD and non-AD (including other neurological pathologies) participants, by means of an analytical method based on liquid chromatography coupled with mass spectrometry. Statistical analysis evaluated correlations between biological matrices. The results did not show satisfactory correlations between plasma and CSF samples for any of the studied lipid peroxidation biomarkers (isoprostanes, neuroprostanes, prostaglandines, dihomo-isoprostanes). However, some of the analytes showed correlations with specific CSF biomarkers for AD and with neuropsychological tests (Mini-Mental State Examination (MMSE), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)). In conclusion, lipid peroxidation biomarkers in CSF samples do not reflect their levels in plasma samples, and no significant differences were observed between participant groups. However, some of the analytes could be useful as cognitive decline biomarkers.

Published
2020

27. Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry

Author

Colomino, M, Beltran, B, Fernandez-Clotet, A, Flores, E, Navarro, P, Rivero, M, Gutierrez, A, Sierra-Ausin, M, Mesonero, F, Ferreiro-Iglesias, R, Hinojosa, J, Calvet, X, Sicilia, B, Gonzalez-Munoza, C, Antolin, B, Vivo, M, Carbajo, A, Garcia, S, Martin-Cardona, A, Marin, G, Martin-Arranz, M, De Francisco, R, Canete, F, Carlos, T, Gomollon, F, Lorente, R, Rodriguez-Lago, I, Fores-Bosch, A, Bernardos, E, Ramos, L, Delgado, P, Hernandez, A, Van Domselaar, M, Hervas, D, Domenech, E, and Nos, P

Published
2020

28. Fecal calprotectin in healthy children aged 4-16 years

Author

Roca M, Rodriguez Varela A, Carvajal E, Donat E, Cano F, Armisen A, Vaya MJ, Ekoff H, Hervas D, Rydell N, and Ribes-Koninckx C

Abstract

Reference values of fecal calprotectin (fCP) have not been convincingly established in children. We aimed to investigate fCP concentrations in a larger population of healthy children aged 4-16 years to analyze more in depth the behavior of fCP in this age range and to determine if cut-off levels could be conclusively recommended. A prospective study was conducted to investigate fCP concentrations of healthy children aged 4-16 years. In 212 healthy children, the median and 95th percentile for fCP were 18.8 mg/kg and 104.5 mg/kg, respectively. We found a statistically significant association between the 95th percentile of fCP concentrations and age (p < 0.001). We propose a nomogram to facilitate the interpretation of fCP results in children aged 4-16 years. Further studies are required to validate the proposed values in clinical practice.

Published
2020

29. Predictors for Anastomotic Leak, Postoperative Complications, and Mortality After Right Colectomy for Cancer: Results From an International Snapshot Audit

Author

Gallo, G., Pata, F., Vennix, S., Laurberg, S., Morton, D., Rubbini, M., Vaizey, C., Magill, L., Perry, R., Sheward, N., Hervas, D., Cillo, M., Estefania, D., Uriburu, J.P., Ruiz, H., Solomon, M., Makhmudov, A., Selnyahina, L., Varabei, A., Vizhynis, Y., Claeys, D., Defoort, B., Muysoms, F., Pletinckx, P., Vergucht, V., Debergh, I., Feryn, T., Reusens, H., Nachtergaele, M., Francart, D., Jehaes, C., Markiewicz, S., Monami, B., Weerts, J., Houben, B., Haeck, L., Lange, C., Sommeling, C., Vindevoghel, K., Castro, S., De Bruyn, H., Huyghe, M., De Wolf, E., Reynders, D., D'Hoore, A., De Buck Van Overstraeten, A., Wolthuis, A., Delibegovic, S., Christiani, A., Marchiori, M., Jr., De Moraes, C.R., Tercioti, V., Jr., Arabadjieva, E., Bulanov, D., Dardanov, D., Stoyanov, V., Yonkov, A., Angelov, K., Maslyankov, S., Sokolov, M., Todorov, G., Toshev, S., Georgiev, Y., Karashmalakov, A., Zafirov, G., Wang, X., Condic, D., Kraljik, D., Mrkovic, H., Pavkovic, V., Raguž, K., Bencurik, V., Holášková, E., Skrovina, M., Farkašová, M., Grolich, T., Kala, Z., Antos, F., Pruchova, V., Sotona, O., Chobola, M., Dusek, T., Ferko, A., Örhalmi, J., Hoch, J., Kocian, P., Martinek, L., Bernstein, I., Sunesen, K.G., Leunbach, J., Thorlacius-Ussing, O., Oveson, A.U., Christensen, P., Chirstensen, S.D., Gamez, V., Oeting, M., Loeve, U.S., Ugianskis, A., Jessen, M., Krarup, P., Linde, K., Mirza, Q., Stovring, J.O., Erritzøe, L., Jakobsen, H.L., Lykke, J., Colov, E.P., Madsen, A.H., Friis, T.L., Funder, J.A., Dich, R., Kjar, S., Rasmussen, S., Schlesinger, N., Kjaer, M.D., Qvist, N., Khalid, A., Ali, G., El-Hussuna, A., Hadi, S., Walker, L.R., Kivelä, A., Lehtonen, T., Lepistö, A., Scheinin, T., Siironen, P., Kössi, J., Kuusanmäki, P., Tomminen, T., Turunen, A., Rautio, T., Vierimaa, M., Huhtinen, H., Karvonen, J., Lavonius, M., Rantala, A., Varpe, P., Cotte, E., Francois, Y., Glehen, O., Kepenekian, V., Passot, G., Maggiori, L., Manceau, G., Panis, Y., Gout, M., Rullier, E., Van Geluwe, B., Chafai, N., Lefevre, J., Parc, Y., Tire, E., Couette, C., Duchalais, E., Agha, A., Hornberger, M., Hungbauer, A., Iesalnieks, I., Weindl, I., Crescenti, F., Keller, M., Kolodziejski, N., Scherer, R., Sterzing, D., Bock, B., Boehm, G., El-Magd, M., Krones, C., Niewiera, M., Buhr, J., Cordesmeyer, S., Hoffmann, M., Krückemeier, K., Vogel, T., Schön, M., Baral, J., Lukoschek, T., Münch, S., Pullig, F., Horisberger, K., Kienle, P., Magdeburg, J., Post, S., Batzalexis, K., Germanos, S., Agalianos, C., Dervenis, C., Gouvas, N., Kanavidis, P., Kottikias, A., Katsoulis, I., Korkolis, D., Plataniotis, G., Sakorafas, G., Akrida, I., Argentou, M., Kollatos, C., Lampropoulos, C., Tsochatzis, S., Besznyák, I., Bursics, A., Egyed, T., Papp, G., Svastics, I., Atladottir, J., Möller, P., Sigurdsson, H., Stefánsson, T., Valsdottir, E., Andrews, E., Foley, N., Hechtl, D., Majeed, M., McCourt, M., Hanly, A., Hyland, J., Martin, S., O'Connell, R., Winter, D., Connelly, T., Joyce, W., Wrafter, P., Berkovitz, R., Avital, S., Yahia, I.H., Herman, N., Shpitz, B., White, I., Lishtzinsky, Y., Tsherniak, A., Wasserberg, N., Horesh, N., Keler, U., Pery, R., Shapiro, R., Zmora, O., Tulchinsky, H., Badran, B., Dayan, K., Iskhakov, A., Lecaros, J., Nabih, N., Angrima, I., Bardini, R., Pizzolato, E., Tonello, M., Arces, F., Balestri, R., Ceccarelli, C., Prosperi, V., Rossi, E., Giannini, I., Vincenti, L., Di Candido, F., Di Iena, M., Guglielmi, A., Iambrenghi, O., Marsanic, P., Mellano, A., Muratore, A., Annecchiarico, M., Bencini, L., Bonapasta, S., Coratti, A., Guerra, F., Asteria, C., Boccia, L., Gerard, L., Pascariello, A., Manca, G., Marino, F., Casaril, A., Inama, M., Moretto, G., Bacchelli, C., Carvello, M., Mariani, N., Montorsi, M., Spinelli, A., Romairone, E., Scabini, S., Belli, A., Bianco, F., De Franciscis, S., Romano, G.M., Delrio, P., Pace, U., Rega, D., Sassaroli, C., Scala, D., De Luca, R., Ruggieri, E., Elbetti, C., Garzi, A., Romoli, L., Scatizzi, M., Vannucchi, A., Curletti, G., Durante, V., Galleano, R., Mariani, F., Reggiani, L., Bellomo, R., Infantino, A., Franceschilli, L., Sileri, P., Clementi, I., Coletta, D., La Torre, F., Mingoli, A., Velluti, F., Di Giacomo, A., Fiorot, A., Massani, M., Padoan, L., Ruffolo, C., Caruso, S., Franceschini, F., Laessig, R., Monaci, I., Rontini, M., De Nardi, P., Lemma, M., Rosati, R., Tamburini, A., De Luca, M., Sartori, A., Benevento, A., Bottini, C., Ferrari, C., Tessera, G., Pellino, G., Selvaggi, F., Lanzani, A., Romano, F., Sgroi, G., Steccanella, F., Turati, L., Yamamoto, T., Ancans, G., Gerkis, S., Leja, M., Pcolkins, A., Sivins, A., Latkauskas, T., Lizdenis, P., Saladžinskas, Ž., Švagždys, S., Tamelis, A., Razbadauskas, A., Sokolovas, M., Dulskas, A., Samalavicius, N., Jotautas, V., Mikalauskas, S., Poskus, E., Poskus, T., Strupas, K., Camenzuli, C., Cini, C., Predrag, A., Psaila, J., Spiteri, N., Bemelman, W., Buskens, C., De Groof, J., Gooszen, J., Tanis, P., Belgers, E., Davids, P., Furnee, E., Postma, E., Pronk, A., Smakman, N., Clermonts, S., Zimmerman, D., Omloo, J., Van Der Zaag, E., Van Duijvendijk, P., Wassenaar, E., Bruijninckx, M., De Graff, E., Doornebosch, P., Tetteroo, G., Vermaas, M., Iordens, G., Knops, S., Toorenvliet, B., Van Westereenen, E., Boerma, E., Coene, P., Van Der Harst, E., Van Der Pool, A., Raber, M., Melenhorst, J., De Castro, S., Gerhards, M., Arron, M., Bremers, A., De Wilt, H., Ferenschild, F., Yauw, S., Cense, H., Demirkiran, A., Hunfeld, M., Mulder, I., Nonner, J., Swank, H., Van Wagensveld, B., Bolmers, M., Briel, J., Van Geloven, N., Van Rossem, C., Klemann, V., Konsten, J., Leenders, B., Schok, T., Bleeker, W., Gidwani, A., Lawther, R., Loughlin, P., Skelly, B., Spence, R., Brun, M., Helgeland, M., Ignjatovic, D., Øresland, T., Peyman, Y., Backe, I.F., Sjo, O.H., Nesbakken, A., Tandberg-Eriksen, M., Cais, A., Traland, J.H., Herikstad, R., Kørner, H., Lauvland, N., Jajtner, D., Kabiesz, W., Rak, M., Gmerek, L., Horbacka, K., Horst, N., Krokowicz, P., Kwiatkowski, A., Pasnik, K., Karcz, P., Romaniszyn, M., Rusek, T., Walega, P., Czarencki, R., Obuszko, Z., Sitarska, M., Wojciech, W., Zawadzki, M., Amado, S., Clara, P., Couceiro, A., Malaquias, R., Rama, N., Almeida, A., Barbosa, E., Cernadas, E., Duarte, A., Silva, P., Costa, S., Insua, C.M., Pereira, J., Pereira, C., Sacchetti, M., Ferreira, R.A.M., Pinto, B.C., Sousa, P.J.V., Oliveira, A., Cardoso, R., Carlos, S., Corte-Real, J., Pereira, P.M., Souto, R., Carneiro, C., Marinho, R., Nunes, V., Rocha, R., Sousa, M., Leite, J., Melo, F., Pimentel, J., Ventura, L., Nova, C.V., Copǎescu, C., Bintintan, V., Ciuce, C., Dindelegan, G., Scurtu, R., Seicean, R., Domansky, N., Karachun, A., Moiseenko, A., Pelipas, Y., Petrov, A., Pravosudov, I., Aiupov, R., Akmalov, Y., Parfenov, A., Suleymanov, N., Tarasov, N., Jumabaev, H., Mamedli, Z., Rasulov, A., Aliev, I., Chernikovskiy, I., Kochnev, V., Komyak, K., Smirnov, A., Achkasov, S., Bolikhov, K., Shelygin, Y., Sushkov, O., Zapolskiy, A., Gvozdenovic, M., Jovanovic, D., Lausevic, Z., Cvetković, D., Maravić, M., Milovanovic, B., Stojakovic, N., Tripković, I., Mihajlovic, D., Nestorovic, M., Pecic, V., Petrovic, D., Stanojevic, G., Barisic, G., Dimitrijevic, I., Krivokapic, Z., Markovic, V., Popovic, M., Aleksic, A., Dabic, D., Kostic, I., Milojkovic, A., Perunicic, V., Dragana, R., Lukic, D., Petrovic, T., Radovanovic, Z., Cuk, V., Kenic, M., Kovacevic, B., Krdzic, I., Korcek, J., Rems, M., Toplak, J., Escarrâ, J., Barrionuevo, M.G., Golda, T., Moreno, E.K., Martin, C.Z., Laso, C.A., Cumplido, P., Padin, H., Fons, J.B., Hernández-Lizoain, J., Martinez-Ortega, P., Molina-Fernández, M., Sánchez-Justicia, C., Solanas, J.A.G., De Laspra, E.C.D., Elia-Guedea, M., Gallego, E., Ramirez, J., Chaves, J.A., González, P.D., Elosua, T., Sahagún, J., Frade, A.T., Conde, J.A., Castrillo, E., Maag, R.D., Maderuelo, V., Saldarriaga, L., Cao, I.A., Varela, X.F., Fernández, S.N., Calvo, A.P., Álvarez, S.V., Sierra, I.B., Lozano, R., Márquez, M., Porcel, O., Menendez, P., Hevia, M.F., Sigüenzo, L.F., Toscano, M.J., Fortuny, A.L., Trujillo, J.O., Espi, A., Garcia-Botello, S., Martín-Arévalo, J., Moro-Valdezate, D., Pla-Martí, V., Blanco-Antona, F., Abrisqueta, J., Canovas, N.I., Mompean, J.L., Ripoll, D.E., Gonzalez, S.M., Parodi, J., López, A.F., Fernández, M.R., Valls, J.C., De Zarate, L.O., Ribas, R., Sabia, D., Viso, L., Gonçalves, S.A., Egea, M.J.G., Damieta, M.P., Pera, M., Ruiz, S.S., Bernal, J., Landete, F., Ais, G., Alonso, E., Lucia, J.A., Boscá, A., Deusa, S., Del Caño, J.G., Viciano, V., García-Armengol, J., Roig, J., Blas, J., Escartin, J., Fatás, J., Fernando, J., Ferrer, R., Pacheco, R.A., Flórez, L.G., Gijón, M.M., Díez, J.O., Garcia, L.S., Teixido, F.A., Ojo, C.B., Berzosa, J.B., Moure, S.L., Sierra, J.E., Fermiñán, A., Herrerias, F., Rufas, M., Viñas, J., Codina-Cazador, A., Farrés, R., Gómez, N., Julià, D., Planellas, P., López, J., Luna, A., Maristany, C., Duyos, A.M., Puértolas, N., Moral, M.A., Serra-Aracil, X., Coello, P.C., Gómez, D., Carton, C., Miguel, A., Pascual, F.R., Cerrato, X.V., Muñoz, R.Z., Cervera-Aldama, J., González, J.G., Ramos-Prada, J., Santamaría-Olabarrieta, M., Urigüen-Echeverría, A., Alcover, R.C., Soria, J.E., Rodriguez, E.F., Hernandis, J., Ibañez, V.M., De La Torre Gonzalez, F., Huerga, D., Viejo, E.P., Rivera, A., Ucar, E.R., Garcia-Septiem, J., Jiménez, V., Miramón, J.J., Rodriquez, J.R., Alvarez, V.R., Garcea, A., Ponchietti, L., Borda, N., Enriquez-Navascues, J., Saralegui, Y., Molina, G.F., Nogues, E., Méndez, A.R., Castellano, C.R., Quesada, Y.S., Gallego, M., Pascual, I., Perez, I., San Andrés, B., Villanueva, F., Alonso, J., Cagigas, C., Castillo, J., Gómez, M., Martín-Parra, J., Ballester, M.M., Franco, E.P., Aledo, V.S., Navarro, G.V., Rodriquez, E.C., De Chaves, P.G., Hernandez, G., Alvarez, A.P., Sanchez, A.S., Garcia, F.C.B., Roque, J.G.A., Aria, F.L.R., Del Valle Ruiz, S.R., De La Villa, G.S., Compañ, A., Marín, A.G., Nofuentes, C., Micó, F.O., Auladell, V.P., Carrasco, M., Perez, C.D., Gálvez-Pastor, S., Garcia, I.N., Perez, A.S., Enjuto, D., Bujalance, F.M., Marcelin, N., Pérez, M., García, R.S., Cabrera, A., De La Portilla, F., Diaz-Pavon, J., Jimenez-Rodriguez, R., Vazquez-Monchul, J., González, J.D., Pérez, R.G., Castellano, J.R., De La Rua, J.R., Toral, B.C., Alustiza, J.E., Fernández, L., Ramirez, J.R., Ramos, J.S., Alias, D., Garcia-Olmo, D., Guadalajara, H., Herreros, M., Pacheco, P., Del Castillo Díez, F., Pinto, F.L., Alegre, J.M., Ortega, I., Antonio, A.P.N., Caro, A., Escuder, J., Feliu, F., Millan, M., Company, R.A., Caregnato, A.F., Trujillo, R.L., Carrillo, R.R., Carmona, M.R., Alonso, N., Zafra, D.A., Candia, B.A.A., Pascual, J.B., Flores, C.P., Montero, J.A., Clavijo, M.A., Garcia, J., Tocino, J.S., Alcazar, C., Navarro, D.C., Romero, J.F., Riveiro, M.R., Romero, M., Arencibia, B., Esclapez, P., Frasson, M., García-Granero, E., Granero, P., Herrera, A.B.G., Diaz, L., Tordera, E.M.T., Fernandez, F.M., Rodriguez, E.N., Arenal, J., Citores, M., Marcos, J., Sánchez, J., Tinoco, C., Espin, E., Granero, A.G., Gomez, L.J., Garcia, J.S., Vallribera, F., Folkesson, J., Sköldberg, F., Bergman, K., Borgström, E., Frey, J., Silfverberg, A., Söderholm, M., Nygren, J., Segelman, J., Gustafsson, D., Lagerqvist, A., Papp, A., Pelczar, M., Abraham-Nordling, M., Ahlberg, M., Sjovall, A., Tengstrom, J., Hagman, K., Chabok, A., Ezra, E., Nikberg, M., Smedh, K., Tiselius, C., Al-Naimi, N., Dao Duc, M., Meyer, J., Mormont, M., Ris, F., Prevost, G., Villiger, P., Hoffmann, H., Kettelhack, C., Kirchhoff, P., Oertli, D., Weixler, B., Aytac, B., Leventoglu, S., Mentes, B., Yuksel, O., Demirbas, S., Ozkan, B.B., Özbalci, G.S., Sungurtekin, Uğur, Gülcü, B., Ozturk, E., Yilmazlar, T., Challand, C., Fearnhead, N., Hubbard, R., Kumar, S., Arthur, J., Barben, C., Skaife, P., Slawik, S., Williams, M., Zammit, M., Barker, J., French, J., Sarantitis, I., Slawinski, C., Clifford, R., Eardley, N., Johnson, M., McFaul, C., Vimalachandran, D., Allan, S., Bell, A., Oates, E., Shanmugam, V., Brigic, A., Halls, M., Pucher, P., Stubbs, B., Agarwal, T., Chopada, A., Mallappa, S., Pathmarajah, M., Sugden, C., Brown, C., Macdonald, E., Mckay, A., Richards, J., Robertson, A., Kaushal, M., Patel, P., Tezas, S., Touqan, N., Ayaani, S., Marimuthu, K., Piramanayagam, B., Vourvachis, M., Iqbal, N., Korsgen, S., Seretis, C., Shariff, U., Arnold, S., Battersby, N.J., Chan, H., Clark, E., Fernandes, R., Moran, S., Bajwa, A., McArthur, D., Cao, K., Cunha, P., Pardoe, H., Quddus, A., Theodoropoulou, K., Bolln, C., Denys, G., Gillespie, M., Manimaran, N., Reidy, J., Malik, A., Pitt, J., Aryal, K., El-Hadi, A., Lal, R., Pal, A., Velchuru, V., Chaudhri, S., Cunha, M.O., Singh, B., Thomas, M., Bains, S., Boyle, K., Miller, A., Norwood, M., Yeung, J., Goian, L., Gurjar, S., Saghir, W., Sengupta, N., Stewart-Parker, E., Bailey, S., Khalil, T., Lawes, D., Nikolaou, S., Omar, G., Church, R., Muthiah, B., Garrett, W., Marsh, P., Obeid, N., Chandler, S., Coyne, P., Evans, M., Hunt, L., Lim, J., Oliphant, Z., Papworth, E., Weaver, H., Leon, K.C., Williams, G., Hernon, J., Kapur, S., Moosvi, R., Shaikh, I., Swafe, L., Aslam, M., Evans, J., Ihedioha, U., Kang, P., Merchant, J., Hompes, R., Middleton, R., Broomfield, A., Crutten-Wood, D., Foster, J., Nash, G., Akhtar, M., Boshnaq, M., Eldesouky, S., Mangam, S., Rabie, M., Ahmed, J., Khan, J., Goh, N.M., Shamali, A., Stefan, S., Nepogodiev, D., Pinkney, T.D., Thompson, C., Amin, A., Docherty, J., Lim, M., Walker, K., Watson, A., Hossack, M., Mackenzie, N., Paraoan, M., Alam, N., Daniels, I., Narang, S., Pathak, S., Smart, N., Al-Qaddo, A., Codd, R., Rutka, O., Bronder, C., Crighton, I., Davies, E., Raymond, T., Bookless, L., Griffiths, B., Plusa, S., Carlson, G., Harrison, R., Lees, N., Mason, C., Quayle, J., Branagan, G., Broadhurst, J., Chave, H., Sleight, S., Awad, F., Bhangu, A., Cruickshank, N., Joy, H., Boereboom, C., Daliya, P., Dhillon, A., Watson, N., Watson, R., Artioukh, D., Gokul, K., Javed, M., Kong, R., Sutton, J., Faiz, O., Jenkins, I., Leo, C., Samaranayake, F., Warusavitarne, J., Arya, S., Bhan, C., Mukhtar, H., Oshowo, A., Wilson, J., Duff, S., Fatayer, T., Mbuvi, J., Sharma, A., Cornish, J., Davies, L., Harries, R., Morris, C., Torkington, J., Knight, J., Lai, C., Shihab, O., Tzivanakis, A., Hussain, A., Luke, D., Padwick, R., Torrance, A., Tsiamis, A., Dawson, P., Balfour, A., Brady, R., Mander, J., Paterson, H., Chandratreya, N., Chu, H., Cutting, J., Vernon, S., Ho, C.W., Andreani, S., Patel, H., Warner, M., Tan, J.Y.Q., Iqbal, A., Khan, A., Perrin, K., Raza, A., Tan, S., European Society of Coloproctology Collaborating Group Collaborators, Group, ESCP Cohort Studies Sub-Committee, ESCP Research Committee, Logistical Support and Data Collection, Analysis, Investigators, Radiology and nuclear medicine, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Surgery, MUMC+: MA Heelkunde (9), Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Cancer Treatment and Quality of Life, Neurology, and Center for Evidence Based Education

Subjects
Male, Leak, Conference Paper, adverse event, ileostomy, non-smoker, 0302 clinical medicine, middle aged, antibiotic therapy, 80 and over, antibiotic agent, postoperative complication, emergency surgery, Colectomy, cecum, Aged, 80 and over, OUTCOMES, adult, COLON-CANCER, Gastroenterology, operation duration, clinical trial, General Medicine, cohort analysis, laparoscopic surgery, ureter injury, Survival Rate, aged, risk factor, 030220 oncology & carcinogenesis, Cohort, kidney injury, 030211 gastroenterology & hepatology, Colonic Neoplasms/mortality, anastomosis leakage, liver injury, prospective study, medicine.medical_specialty, SURGICAL STRESS, ELECTIVE RIGHT, surgical infection, 03 medical and health sciences, Humans, human, Aged, clinical audit, sex ratio, major clinical study, mortality, hemicolectomy, multicenter study, RISK-FACTORS, observational study, Complication, Anastomotic leak, Colon cancer, Postoperative outcome, Right colectomy, general surgery, surgical mortality, SURGERY, very elderly, morbidity, Anastomotic Leak, mortality rate, open surgery, Cohort Studies, Postoperative Complications, gallbladder disease, LAPAROSCOPY, Risk Factors, Neoplasms, cancer mortality, Laparoscopy, Prospective cohort study, colon resection, Medical Audit, medicine.diagnostic_test, Mortality rate, colon tumor, Middle Aged, female, colon cancer, Right Colectomy, Colonic Neoplasms, ileum, surgical stapling, Female, cancer surgery, Colectomy/adverse effects, duodenum injury, small intestine resection, RESECTION, reoperation, Anastomosis, NO, MORBIDITY, medicine, operative blood loss, LS7_4, percutaneous drainage, business.industry, suture technique, Surgery, blood vessel injury, peroperative complication, elective surgery, Anastomotic Leak/epidemiology, pathology, business
Abstract

A right hemicolectomy is among the most commonly performed operations for colon cancer, but modern high-quality, multination data addressing the morbidity and mortality rates are lacking.This study reports the morbidity and mortality rates for right-sided colon cancer and identifies predictors for unfavorable short-term outcome after right hemicolectomy.This was a snapshot observational prospective study.The study was conducted as a multicenter international study.The 2015 European Society of Coloproctology snapshot study was a prospective multicenter international series that included all patients undergoing elective or emergency right hemicolectomy or ileocecal resection over a 2-month period in early 2015. This is a subanalysis of the colon cancer cohort of patients.Predictors for anastomotic leak and 30-day postoperative morbidity and mortality were assessed using multivariable mixed-effect logistic regression models after variables selection with the Lasso method.Of the 2515 included patients, an anastomosis was performed in 97.2% (n = 2444), handsewn in 38.5% (n = 940) and stapled in 61.5% (n = 1504) cases. The overall anastomotic leak rate was 7.4% (180/2444), 30-day morbidity was 38.0% (n = 956), and mortality was 2.6% (n = 66). Patients with anastomotic leak had a significantly increased mortality rate (10.6% vs 1.6% no-leak patients; p0.001). At multivariable analysis the following variables were associated with anastomotic leak: longer duration of surgery (OR = 1.007 per min; p = 0.0037), open approach (OR = 1.9; p = 0.0037), and stapled anastomosis (OR = 1.5; p = 0.041).This is an observational study, and therefore selection bias could be present. For this reason, a multivariable logistic regression model was performed, trying to correct possible confounding factors.Anastomotic leak after oncologic right hemicolectomy is a frequent complication, and it is associated with increased mortality. The key contributing surgical factors for anastomotic leak were anastomotic technique, surgical approach, and duration of surgery. See Video Abstract at http://links.lww.com/DCR/B165. PREDICTORES DE FUGA ANASTOMóTICA, COMPLICACIONES POSTOPERATORIAS Y MORTALIDAD DESPUéS DE LA COLECTOMíA DERECHA POR CáNCER: RESULTADOS DE UNA AUDITORíA INTERNACIONAL DE CORTO PLAZO: La hemicolectomía derecha se encuentra entre las operaciones más frecuentemente realizadas para cáncer de colon, pero faltan datos modernos multinacionales de alta calidad, que aborden las tasas de morbilidad y mortalidad.Reportar la tasa de morbilidad y mortalidad para cáncer de colon del lado derecho, e identificar predictores de resultados desfavorables a corto plazo, después de la hemicolectomía derecha.Estudio prospectivo observacional de corto plazo.Estudio multicéntrico internacional.El estudio de corto plazo de la Sociedad Europea de Coloproctología de 2015, fue una serie prospectiva multicéntrica internacional, que incluyó a todos los pacientes sometidos a hemicolectomía derecha electiva, de emergencia o resección ileocecal, por un período de dos meses y a principios de 2015. Este es un subanálisis, cohorte de pacientes con cáncer de colon.Los predictores de fuga anastomótica, morbilidad y mortalidad postoperatorias a los 30 días, se evaluaron usando modelos de regresión logística de efectos multivariables mixtos, después de la selección de variables con el método Lasso.De los 2,515 pacientes incluidos, se realizó una anastomosis en el 97,2% (n = 2,444); sutura manual en 38.5% (n = 940) y por engrapadora en 61.5% (n = 1504) casos. La tasa global de fuga anastomótica fue del 7,4% (180/2,444), morbilidad a los 30 días fue del 38,0% (n = 956) y la mortalidad fue del 2,6% (n = 66). Los pacientes con fuga anastomótica tuvieron una tasa de mortalidad significativamente mayor (10,6% frente al 1,6% de pacientes sin fuga, p0,001). En el análisis multivariable, las siguientes variables se asociaron con la fuga anastomótica: mayor duración de la cirugía (OR 1.007 por minuto, p = 0.0037), abordaje abierto (OR 1.9, p = 0.0037) y anastomosis por engrapadora (OR 1.5, p = 0.041).Este es un estudio observacional y por lo tanto podría estar presente el sesgo de selección. Por esta razón, se realizó un modelo de regresión logística multivariable, tratando de corregir posibles factores de confusión.La fuga anastomótica después de la hemicolectomía derecha oncológica, es una complicación frecuente y asociada a mayor mortalidad. Los factores quirúrgicos clave que contribuyeron a la fuga anastomótica, fueron la técnica anastomótica, abordaje quirúrgico y duración de la cirugía. Consulte Video Resumen en http://links.lww.com/DCR/B165. (Traducción-Dr. Fidel Ruiz Healy).

Published
2020
Full Text
View/download PDF

31. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids

Author

Alcala, N, Leblay, N, Gabriel, A A G, Mangiante, L, Hervas, D, Giffon, T, Sertier, A S, Ferrari, A, Derks, J, Ghantous, A, Delhomme, T M, Chabrier, A, Cuenin, C, Abedi-Ardekani, B, Boland, A, Olaso, R, Meyer, V, Altmuller, J, Le Calvez-Kelm, F, Durand, G, Voegele, C, Boyault, S, Moonen, L, Lemaitre, N, Lorimier, P, Toffart, A C, Soltermann, A, Clement, J H, Saenger, J, Field, J K, et al, and University of Zurich

Subjects
1300 General Biochemistry, Genetics and Molecular Biology, 10049 Institute of Pathology and Molecular Pathology, 610 Medicine & health, 1600 General Chemistry, 3100 General Physics and Astronomy
Published
2019
Full Text
View/download PDF

33. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry

Author

Iborra, M, Beltran, B, Fernandez-Clotet, A, Gutierrez, A, Antolin, B, Huguet, J, De Francisco, R, Merino, O, Carpio, D, Garcia-Lopez, S, Mesonero, F, Navarro, P, Ferreiro-Iglesias, R, Carbajo, A, Rivero, M, Gisbert, J, Pinero-Perez, M, Monfort, D, Bujanda, L, Garcia-Sepulcre, M, Martin-Cardona, A, Canete, F, Taxonera, C, Domenech, E, Nos, P, Sierra-Ausin, M, Ferrer-Rosique, J, Martin-Arranz, M, Gonzalez-Munoza, C, Mancenido, N, Rodriguez-Lago, I, Benitez, J, Fores-Bosch, A, Navarro-Llavat, M, Calafat, M, Madrigal-Dominguez, R, Ramos, L, Arroyo, M, Busquets, D, Lorente, R, Sainz-Arnau, E, Hernandez-Camba, A, Morales-Alvarado, V, Paredes, J, Van Domselaar, M, Hervas, D, Canada-Martinez, A, Castro-Poceiro, J, Cameo-Lorenzo, J, Fernandez-Salazar, L, Riestra, S, Casas-Deza, D, Tosca, J, Barrio, J, Garcia, M, Chaparro, M, and GETECCU Grp Grp Espanol Trab

Abstract

Background There are limited data of ustekinumab administered according to the doses recommended in the UNITI studies. Aim To assess the real-world, short-term effectiveness of ustekinumab in refractory Crohn's disease (CD) Methods Multicentre study of CD patients starting ustekinumab after June 2017 at the recommend dose (260, 390 or 520 mg based on weight ~6 mg/kg IV week 0 and 90 mg subcutaneously week 8). Values for Harvey-Bradshaw Index (HBI), C-reactive protein (CRP) and faecal calprotectin (FC) were recorded at baseline and at weeks 8 and 14. Demographic and clinical data, previous treatments, AEs and hospitalisations were documented. Possible predictors of clinical remission were examined. Results Three hundred and five patients were analysed (>= 2 previous anti-TNF alpha therapies 64% and vedolizumab 29%). At baseline, 217 (72%) had an HBI >4 points. Of these, 101 (47%) and 126 (58%) achieved clinical remission at weeks 8 and 14, respectively. FC levels returned to normal (

Published
2019

34. Topiramate plus Cooling for Hypoxic-Ischemic Encephalopathy: A Randomized, Controlled, Multicenter, Double-Blinded Trial

Author

Nunez-Ramiro, A, Benavente-Fernandez, I, Valverde, E, Cordeiro, M, Blanco, D, Boix, H, Cabanas, F, Chaffanel, M, Fernandez-Colomer, B, Fernandez-Lorenzo, JR, Kuligowski, J, Loureiro, B, Moral-Pumarega, MT, Pavon, A, Sanchez-Illana, A, Tofe, I, Hervas, D, Garcia-Robles, A, Parra-Llorca, A, Cernada, M, Martinez-Rodilla, J, Lorente-Pozo, S, Llorens, R, Marques, R, Vento, M, and Hypotop Study Grp

Subjects
Seizures, Hypoxic-ischemic encephalopathy, Oxidative stress biomarkers, Hyperexcitability, Anaerobic metabolism
Abstract

Background and Objectives: Therapeutic interventions to improve the efficacy of whole-body cooling for hypoxic-ischemic encephalopathy (HIE) are desirable. Topiramate has been effective in reducing brain damage in experimental studies. However, in the clinical setting information is limited to a small number of feasibility trials. We launched a randomized controlled double-blinded topiramate/placebo multicenter trial with the primary objective being to reduce the antiepileptic activity in cooled neonates with HIE and assess if brain damage would be reduced as a consequence. Study Design: Neonates were randomly assigned to topiramate or placebo at the initiation of hypothermia. Topiramate was administered via a nasogastric tube. Brain electric activity was continuously monitored. Topiramate pharmacokinetics, energy-related and Krebs' cycle intermediates, and lipid peroxidation biomarkers were determined using liquid chromatography-mass spectrometry and MRI for assessing brain damage. Results: Out of 180 eligible patients 110 were randomized, 57 (51.8%) to topiramate and 53 (48.2%) to placebo. No differences in the perinatal or postnatal variables were found. The topiramate group exhibited less seizure burden in the first 24 h of hypothermia (topiramate, n = 14 [25.9%] vs. placebo, n = 22 [42%]); needed less additional medication, and had lower mortality (topiramate, n = 5 [9.2%] vs. placebo, n = 10 [19.2%]); however, these results did not achieve statistical significance. Topiramate achieved a therapeutic range in 37.5 and 75.5% of the patients at 24 and 48 h, respectively. A significant association between serum topiramate levels and seizure activity (p < 0.016) was established. No differences for oxidative stress, energy-related metabolites, or MRI were found. Conclusions: Topiramate reduced seizures in patients achieving therapeutic levels in the first hours after treatment initiation; however, they represented only a part of the study population. Our results warrant further studies with higher loading and maintenance dosing of topiramate. (C) 2019 S. Karger AG, Basel

Published
2019

36. Identification of novel synthetic lethal vulnerability in non small cell lung cancer by co targeting TMPRSS4 and DDR1

Author

Villalba-Esparza, M. (María), Redín, E. (Esther), Expósito, F. (Francisco), Pajares, M.J. (María José), Sainz, C. (Cristina), Hervas, D. (D.), Guruceaga, E. (Elizabeth), Diaz-Lagares, A. (Ángel), Cirauqui, C. (Cristina), Redrado, M. (Miriam), Valencia, K. (Karmele), Andrea, C.E. (Carlos Eduardo) de, Jantus-Lewintre, E. (Eloisa), Camps, C. (Carlos), López-López, R. (Rafael), Lahoz, A. (Agustín), Montuenga-Badia, L.M. (Luis M.), Pio, R. (Rubén), Sandoval, J. (Juan), and Calvo-González, A. (Alfonso)

Subjects
Ciencias de la Salud::Oncología [Materias Investigacion]
Abstract

Finding novel targets in non-small cell lung cancer (NSCLC) is highly needed and identification of synthetic lethality between two genes is a new approach to target NSCLC. We previously found that TMPRSS4 promotes NSCLC growth and constitutes a prognostic biomarker. Here, through large-scale analyses across 5 public databases we identified consistent co-expression between TMPRSS4 and DDR1. Similar to TMPRSS4, DDR1 promoter was hypomethylated in NSCLC in 3 independent cohorts and hypomethylation was an independent prognostic factor of disease-free survival. Treatment with 5-azacitidine increased DDR1 levels in cell lines, suggesting an epigenetic regulation. Cells lacking TMPRSS4 were highly sensitive to the cytotoxic effect of the DDR1 inhibitor dasatinib. TMPRSS4/DDR1 double knock-down (KD) cells, but not single KD cells suffered a G0/G1 cell cycle arrest with loss of E2F1 and cyclins A and B, increased p21 levels and a larger number of cells in apoptosis. Moreover, double KD cells were highly sensitized to cisplatin, which caused massive apoptosis (~40%). In vivo studies demonstrated tumor regression in double KD-injected mice. In conclusion, we have identified a novel vulnerability in NSCLC resulting from a synthetic lethal interaction between DDR1 and TMPRSS4.

Published
2019

37. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis

Author

Gil-Perotin S, Castillo-Villalba J, Cubas-Nuñez L, Gasque R, Hervas D, Gomez-Mateu J, Alcala C, Perez-Miralles F, Gascon F, Dominguez JA, and Casanova B

Subjects
CHI3L1, NFL, YKL-40, gadolinium-enhancing lesions, progressive multiple sclerosis, progressive multiple sclerosis, YKL-40, CHI3L1, gadolinium-enhancing lesions, NFL
Abstract

Background: Neurofilament light chain protein (NFL) and chitinase3-like1 (CHI3L1) have gained importance recently as prognostic biomarkers in multiple sclerosis (MS). Objectives: We aimed to investigate NFL and CHI3L1 cerebrospinal fluid (CSF) profiles in multiple sclerosis and the informative and prognostic potential of the individual and combined measures. Methods: CSF NFL and CHI3L1 levels were measured in a cross-sectional cohort of 157 MS patients [99 relapsing-remitting (RRMS), 35 secondary progressive (SPMS), and 23 primary progressive (PPMS)]. Clinical relapse and/or gadolinium-enhanced lesions (GEL) in MRI within 90 days from CSF collection by lumbar puncture (LP) were registered and considered as indicators of disease activity. Longitudinal treatment and disability data were evaluated during medical visits with a median follow-up of 50 months. Results: CSF levels of NFL and CHI3L1 were higher in MS patients compared to non-MS controls. In RRMS and SPMS patients, increased NFL levels were associated with clinical relapse, and gadolinium-enhanced lesions in MRI < 0.001), while high CHI3L1 levels were characteristic of progressive disease (p = 0.01). In RRMS patients, CSF NFL, and CHI3L1 levels correlated with each other (r = 0.58), and with IgM-oligoclonal bands (1) = 0.02 and p = 0.004, respectively). In addition, CSF CHI3L1 concentration was a predictor for 1-point EDSS worsening (HR = 2.99 [95% CI (1.27, 7.07)]) and progression during follow-up (HR = 18 [95% CI (2.31, 141.3)]). The pattern of combined measure of biomarkers was useful to discriminate MS phenotypes and to anticipate clinical progression: RRMS more frequently presented high NFL combined with low CHI3L1 levels, compared to SPMS (HR 0.41 [0.18-0.82]), and PPMS (HR 0.46 [0.19-0.87]), while elevation of both biomarkers preceded diagnosis of clinical progression in RRMS patients (log rank = 0.02). Conclusions: Individual measures of CSF NFL and CHI3L1 are biomarkers of disease activity and progression, respectively. The pattern of combined measure discriminates MS phenotypes. It also predicts the subset of RRMS patients that will progress clinically allowing early intervention.

Published
2019

39. P2.03-38 Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1

Author

Redin, E., primary, Villalba, M., additional, Exposito, F., additional, Pajares, M.J., additional, Sainz, C., additional, Hervas, D., additional, Guruceaga, E., additional, Diaz-Lagares, A., additional, Cirauqui, C., additional, Redrado, M., additional, De Andrea, C., additional, Jantus, E., additional, Camps, C., additional, López, R., additional, Lahoz, A., additional, Montuenga, L., additional, Pio, R., additional, Sandoval, J., additional, and Calvo, A., additional

Published
2019
Full Text
View/download PDF

40. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids

Author

Alcala, N; https://orcid.org/0000-0002-5961-5064, Leblay, N, Gabriel, A A G, Mangiante, L, Hervas, D, Giffon, T; https://orcid.org/0000-0001-8133-6507, Sertier, A S, Ferrari, A, Derks, J; https://orcid.org/0000-0002-0442-1879, Ghantous, A, Delhomme, T M; https://orcid.org/0000-0003-0265-4246, Chabrier, A, Cuenin, C, Abedi-Ardekani, B, Boland, A, Olaso, R, Meyer, V, Altmuller, J, Le Calvez-Kelm, F, Durand, G, Voegele, C, Boyault, S; https://orcid.org/0000-0002-2297-6894, Moonen, L, Lemaitre, N, Lorimier, P, Toffart, A C, Soltermann, A, Clement, J H; https://orcid.org/0000-0002-6601-2456, Saenger, J, Field, J K; https://orcid.org/0000-0003-3951-6365, et al, Alcala, N; https://orcid.org/0000-0002-5961-5064, Leblay, N, Gabriel, A A G, Mangiante, L, Hervas, D, Giffon, T; https://orcid.org/0000-0001-8133-6507, Sertier, A S, Ferrari, A, Derks, J; https://orcid.org/0000-0002-0442-1879, Ghantous, A, Delhomme, T M; https://orcid.org/0000-0003-0265-4246, Chabrier, A, Cuenin, C, Abedi-Ardekani, B, Boland, A, Olaso, R, Meyer, V, Altmuller, J, Le Calvez-Kelm, F, Durand, G, Voegele, C, Boyault, S; https://orcid.org/0000-0002-2297-6894, Moonen, L, Lemaitre, N, Lorimier, P, Toffart, A C, Soltermann, A, Clement, J H; https://orcid.org/0000-0002-6601-2456, Saenger, J, Field, J K; https://orcid.org/0000-0003-3951-6365, and et al

Abstract

The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously proposed molecular link between the low- and high-grade lung neuroendocrine neoplasms.

Published
2019

41. HIF-1 alpha stabilization reduces retinal degeneration in a mouse model of retinitis pigmentosa

Author

Olivares-Gonzalez, L, de la Camara, CMF, Hervas, D, Millan, JM, and Rodrigo, R

Subjects
reactive gliosis, genetic structures, inflammation, hyperoxia, DMOG, sense organs, oxidative damage
Abstract

Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterized by progressive and irreversible loss of vision due to rod and cone degeneration. Evidence suggests that an inappropriate oxygen level could contribute to its pathogenesis. Rod cell death could increase oxygen concentration, reduce hypoxia-inducible factor 1 (HIF-1 alpha) and contribute to cone cell death. The purposes of this study were: 1) to analyze the temporal profile of HIF-1 alpha, its downstream effectors VEGF, endothelin-1 (ET-1), iNOS, and glucose transporter 1 (GLUT1), and neuroinflammation in retinas of the murine model of rd10 (retinal degeneration 10) mice with RP; 2) to study oxygen bioavailability in these retinas; and 3) to investigate how stabilizing HIF-1 alpha proteins with dimethyloxaloglycine (DMOG), a prolyl hydroxylase inhibitor, affects retinal degeneration, neuroinflammation, and antioxidant response in rd10 mice. A generalized down-regulation of HIF-la and its downstream targets was detected in parallel with reactive gliosis, suggesting high oxygen levels during retinal degeneration. At postnatal d 18, DMOG treatment reduced photoreceptor cell death and glial activation. In summary, retinas of rd10 mice seem to be exposed to a hyperoxic environment even at early stages of degeneration. HIF-1 alpha stabilization could have a temporal neuroprotective effect on photoreceptor cell survival, glial activation, and antioxidant response at early stages of RP.

Published
2018

42. Anti-gliadin antibodies in breast milk from celiac mothers on a gluten-free diet

Author

Roca, M., Vriezinga, S.L., Crespo-Escobar, P., Auricchio, R., Hervas, D., Castillejo, G., Mena, M.C., Polanco, I., Troncone, R., Mearin, M.L., Ribes-Koninckx, C., and PREVENT CD Study Grp

Subjects
Breast milk, Celiac disease, Gliadin antibodies, Immunoglobulin A
Abstract

To analyze the presence of total IgA and anti-gliadin antibodies (AGA) in BM from CD mothers who follow a gluten-free diet (GFD) and from mothers on a normal gluten-containing diet (ND). 218 samples of mature milk were obtained at different months of lactation (1-6) from 83 mothers (2 or more samples per mother) from Italy (Naples), The Netherlands (Leiden) and Spain (Madrid, Valencia and Reus): 42 CD mothers on GFD for more than 2 years and 41 non-CD mothers on a ND. Whey samples were analyzed for AGA-IgA by an indirect homemade ELISA and for total IgA (g/L) by a commercial ELISA kit. AGA-IgA was detected in BM, both in mothers on a GFD and mothers on a ND. AGA-IgA levels in both groups of mothers, CD and non-CD, show the same trend towards decreasing slightly along the months of lactation (p = 0.91). A different trend is observed for total IgA levels, decreasing markedly in CD mothers from the first month of lactation onwards but remaining stable in non-CD mothers (p = 0.048). A statistically significant association was found between the means of total IgA and AGA-IgA (p < 0.001). AGA-IgA is present in BM from mothers on a ND as well as in BM from mothers who had been on a GFD for years. This reflects the existence of a long-lasting immunological memory independent of the mother's diet. If the presence of these antibodies has any role in promoting the acquisition of gluten tolerance in the infant, our study shows that children of CD mothers would be on equal conditions as children of non-CD mothers.

Published
2018

43. Development and electronic validation of the revised Cystic Fibrosis Questionnaire (CFQ-R Teen/Adult): New tool for monitoring psychosocial health in CF

Author

Sole, A, Olveira, C, Perez, I, Hervas, D, Valentine, V, Baca Yepez AN, Olveira, G, and Quittner, AL

Subjects
Adult, Male, Diagnostic tool, Adolescent, Cystic Fibrosis, Surveys and Questionnaires, Quality of Life, Humans, Female, Patient reported outcomes, Cystic Fibrosis Questionnaire Revised
Abstract

Background: The Cystic Fibrosis Questionnaire-Revised (CFQ-R+ 14) is a disease-specific, health-related quality of life instrument for cystic fibrosis (CF) patients >= 14 years. We have developed a Spanish electronic version of the CFQ-R (e-CFQ-R+ 14 Spain). Our aim was to compare the paper and electronic versions and to validate the electronic version. Methods: Fifty CF patients completed the study. All answered the paper and electronic versions on day 1 and repeated the e-CFQR version 15 days later. Results: Concordance between the electronic and paper copy versions was high, with correlations above 0.9 in all domains. Test-retest reliability of the e-CFQ-R results was strong, with coefficients ranging from 0.8 to 0.9. Conclusions: The e-CFQ-R version is reliable and valid and can replace the paper copy, thus simplifying the assessment of quality of life. It also provides immediate results with no errors in scoring. It is a useful new tool in CF care. (C) 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Published
2017

45. AB0058 Il2 decrease and increase of il10 and inf1a are associated to clinical activity in systemic lupus erythematouspatients

Author

Grau, E., primary, Feced, C., additional, Labrador, E., additional, Ortiz, F.M., additional, Alcañiz, C., additional, Arevalo, K., additional, Chalmeta, I., additional, De la Rubia, M., additional, Fragio, J., additional, Gonzalez, R., additional, Gonzalez, L., additional, Ivorra, J., additional, Martinez, I., additional, Negueroles, R., additional, Oller, J., additional, Vicens, E., additional, Najera, C., additional, Canovas, I., additional, Hervas, D., additional, Fernandez, M., additional, Fernandez-Llanio, N., additional, Castellano, J.A., additional, Mayo, F., additional, and Roman, J.A., additional

Published
2018
Full Text
View/download PDF

46. AB0770 18 fdg pet/ct predicts decline in functional respiratory tests in systemic sclerosis patients but not in rheumatoid arthritis patients

Author

Ivorra, J., primary, Martinez, M., additional, Loaiza, J.L., additional, Garijo, M., additional, Alegre, J.J., additional, Herrera, S., additional, Chalmeta, I., additional, Gonzalez, L., additional, Negueroles, R., additional, Alcañiz, C., additional, Arevalo, K.R., additional, Canovas, I., additional, Feced, C., additional, Fragio, J.J., additional, Gonzalez, R., additional, Grau, E., additional, Labrador, E., additional, Martinez, I., additional, Najera, C., additional, Oller, J.E., additional, Ortiz, F.M., additional, Vicens, E., additional, De la Rubia, M., additional, Hervas, D., additional, and Roman, J.A., additional

Published
2018
Full Text
View/download PDF

47. AB1002 Differences in bone metabolism between intermittent and continuous treatment with lhrh agonists in prostate cancer patients

Author

Arevalo, K.R., primary, Ivorra, J., additional, Vera, C., additional, Grau, E., additional, Chalmeta, I., additional, Gonzalez, L., additional, Negueroles, R., additional, Alcañiz, C., additional, Canovas, I., additional, Feced, C., additional, Fragio, J.J., additional, Gonzalez, R., additional, Labrador, E., additional, Martinez, I., additional, Najera, C., additional, Oller, J.E., additional, Ortiz, F.M., additional, Vicens, E., additional, De la Rubia, M., additional, Hervas, D., additional, and Roman, J.A., additional

Published
2018
Full Text
View/download PDF

48. Standard outcome indicators after colon cancer resection. Creation of a nomogram for autoevaluation

Author

Sancho-Muriel, J, Frasson, M, Hervas, D, Flor-Lorente, B, Ramos Rodriguez JL, Romero Simó M, Escoll Rufino J, Santamaría Olabarrieta M, Viñas Martinez J, López Bañeres M, Garcia-Granero, E, and ANACO Study Group

Subjects
Colon surgery, Outcome assessment, Colonic neoplasms, Quality indicators, Reference standards
Abstract

Introduction: Lately there has been an increasing interest in identifying quality standards in different pathologies, among them colon cancer due to its great prevalence. The main goal of this study is to define the quality standards of colon cancer surgery based on a large prospective national study dataset. Methods: Data from the prospective national study ANACO were used. This study included a consecutive series of patients operated on for colon cancer in 52 Spanish hospitals (20112012). Centers with less than 30 patients were excluded. The present analysis finally included 42 centers (2975 patients). Based on the results obtained in 4 main indicators from each hospital (anastomotic leak, lymph-nodes found in the specimen, mortality and length of stay), a nomogram that allows the evaluation of the performance of each center was designed. Standard results for further 5 intraoperative and 5 postoperative quality indicators were also reported. Results: Median of anastomotic leak and mortality rate was 8.5% (25th-75th percentiles 6.1%12.4%) and 2.5% (25th-75th percentiles 0.6%-4.7%), respectively. Median number of nodes found in the surgical specimen was 15,1 (25th-75th percentiles 18-14 nodes). Median length of postoperative stay was 7.7 days (25th-75th percentiles 6.9-9.2 days). Based on these data, a nomogram for hospital audit was created. Conclusions: Standard surgical results after colon cancer surgery were defined, creating a tool for auto-evaluation and allowing each center to identify areas for improvement in the surgical treatment of colon cancer. (C)2016 AEC. Published by Elsevier Espana, S.L.U. All rights reserved.

Published
2017

49. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients (vol 52, pg 788, 2017)

Author

Iborra M, Gisbert J, Bosca-Watts M, Lopez-Garcia A, Garcia-Sanchez V, Lopez-Sanroman A, Hinojosa E, Marquez L, Garcia-Lopez S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltran B, Rodriguez-Gutierrez C, Barrio J, Cabriada J, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman H, Hervas D, Nos P, and Spanish Working Grp on Crohn's Dis

Published
2017

50. Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients

Author

Gonzalez-Billalabeitia, E, Castellano, D, Sobrevilla, N, Guma, J, Hervas, D, Luengo, MI, Aparicio, J, Sanchez-Munoz, A, Mellado, B, Saenz, A, Valverde, C, Fernandez, A, Margeli, M, Duran, I, Fernandez, S, Sastre, J, Ros, S, Maroto, P, Manneh, R, Cerezuela, P, Carmona-Bayonas, A, Unitat de Recerca en Oncològica, Medicina i Cirurgia, and Universitat Rovira i Virgili

Subjects
Ciències de la salut, Està en blanc, Health sciences, 0027-8874, Càncer, Trombosi venosa, Ciencias de la salud
Abstract

Background: Disseminated germ cell cancers are at high risk of developing thromboembolic complications. We evaluated the prognostic value of venous thromboembolic events (VTE) in disseminated germ cell cancer. Methods: Patients with germ cell cancer receiving upfront platinum-containing chemotherapy between 2004 and 2014 were pooled from the Spanish Germ Cell Cancer Group (SGCCG) registry and reviewed for the presence of VTE. Results were validated in an independent international group of patients. We used a penalized Cox proportional hazards model including VTE as a time-varying covariate to identify and validate prognostic factors. All statistical tests were two-sided. Results: The SGCCG registry identified 416 patients from 14 referral institutions. With a median follow-up of 49 months, VTEs were observed in 9% of patients (n = 38). Events occurred at diagnosis, during chemotherapy, and after chemotherapy in 2.6%, 5.0%, and 1.4% of patients, respectively. VTE was associated with shorter progression-free survival (PFS; hazard ratio [HR] = 2.29, 95% confidence interval [CI] = 1.18 to 4.47, P = .02) and overall survival (OS; HR = 5.14, 95% CI = 2.22 to 11.88, P < .001). In multivariable analysis, the effect was consistent in the intermediate-risk group, both for PFS (HR = 9.52 95% CI = 2.48 to 36.58, P < .001) and OS (HR = 12.84, 95% CI = 2.01 to 82.02, P = .007). VTE at diagnosis is also an adverse prognostic variable for progression-free survival (HR = 4.64, 95% CI = 2.04 to 10.54, P < .001) and for overall survival (HR = 6.28, 95% CI = 1.68 to 17.10, P = .01). These results were validated in an independent international cohort that included 241 patients from four hospitals. Conclusions: VTE is an independent adverse prognostic factor in disseminated germ cell cancers, in particular for the intermediate prognostic group of the International Germ Cell Cancer Collaborative Group classification. The presence of VTE at diagnosis has also prognostic significance and should be further explored in future prognostic classifications.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results